Molcure

Molcure develops an AI-driven molecular design platform for drug discovery, combining proprietary large language models, physics-based simulations, and high-quality experimental data from its in-house biolab to discover effective biotherapeutics against challenging targets. The company's core technology includes a proprietary Antibody LLM built from scratch, a database of over 1 billion proprietary antibody and peptide datapoints, and wet lab capabilities for directed evolution experiments and next-generation sequencing (NGS). Molcure offers four collaboration models: end-to-end AI-driven molecular design with screening and NGS, AI-powered de novo discovery from partner samples, AI-driven lead optimization, and consulting-based problem solving. With 19 partner companies and 28 collaborative projects, the platform has established strong industry traction. Founded in 2013 and headquartered in Tokyo, Japan with a biolab in Tsuruoka, the company has raised approximately $11.7 million at the Series C stage.